Buy daclatasvir 60 mg online
Descriptions
Daclatasvir is a potent and specific inhibitor of the HCV NS5A replication complex. The HCV NS5A is a multifunctional protein with key functions in HCV replication and modulation of cellular signaling pathways. Buy daclatasvir 60 mg online only at $133. To know more about the product visit Contact Us page.
To read more visit: Incepata pharma
Virodacla tablet 28’s(Daclatasvir) Buy Daclatasvir 60 mg Only $133
Presentation
Each Tablet contains Daclatasvir Dihydrochloride INN equivalent to Daclatasvir 60 mg.
Indications
Daclatasvir indicate in combination with Sofosbuvir for the treatment of chronic hepatitis C virus (HCV) infection in adults.
Dosage & Administration
The recommended dose of Daclatasvir is 60 mg once daily, to be taken orally with or without meals. Daclatasvir must be administered in combination with other medicinal products.
HCV-monoinfected or HCV/HIV coinfected patients with chronic hepatitis C without cirrhosis, including treatment-naïve patients and patients who failed on a treatment based on Peginterferon alfa & Ribavirin
– All genotypes: Daclatasvir + Sofosbuvir for 12 weeks
HCV-monoinfected or HCV/HIV coinfected patients with chronic hepatitis C with compensated (Child-Pugh A) cirrhosis, including treatment-naïve patients and patients who failed on a treatment based on Peginterferon alfa & Ribavirin
– Genotype 1,4,5,6: Daclatasvir + Sofosbuvir for 24 weeks or Daclatasvir + Sofosbuvir + Ribavirin for 12 weeks
– 2: Daclatasvir + Sofosbuvir for 12 weeks
– and 3 : Daclatasvir + Sofosbuvir + Ribavirin for 24 weeks
The dose of Ribavirin, when combined with Daclatasvir, is weight-based (1000 or 1200 mg in patients <75 kg or ≥75 kg, respectively).
Side Effects
Daclatasvir in combination with Sofosbuvir
Fatigue, headache, nausea
Daclatasvir in combination with Peginterferon alfa and Ribavirin
The most frequently reported adverse reactions were fatigue, headache, pruritus, insomnia, influenza-like illness, dry skin, nausea, decreased appetite, alopecia, rash, asthenia, irritability, myalgia, anaemia, pyrexia, cough, dyspnoea, neutropenia, diarrhoea and arthralgia. The most frequently reported adverse reactions (frequency of 1% or greater) were neutropenia, anaemia and lymphopenia. The safety profile of daclatasvir in combination with Peginterferon alfa and Ribavirin was similar to that seen with Peginterferon alfa and Ribavirin alone, including among patients with cirrhosis.
Precautions
Bradycardia with Sofobuvir and Amiodarone coadministration: Serious symptomatic bradycardia may occur in patients taking amiodarone with Sofosbuvir in combination with Daclatasvir, particularly in patients also receiving beta blockers, or those with underlying cardiac comorbidities and/or advanced liver disease. Co-administration of amiodarone with Sofobuvir in combination with Daclatasvir not recommend. Daclatasvir must not administer as monotherapy. Daclatasvir must administer in combination with other medicinal products for the treatment of chronic HCV infection
Pharmacodynamics
Daclatasvir is a direct-acting antiviral agent that targets the NS5A and causes a decrease in serum HCV RNA levels. It disrupts HCV replication by specifically inhibiting the critical functions of an NS5A protein in the replication complex. This show to cause downregulation of the hyperphosphorylation of NS5A. However does not appear to prolong the QT interval even when given at 3 times the maximum recommended dose.
Mechanism of action
NS5A is a viral nonstructural phosphoprotein that is part of a functional replication complex in charge of viral RNA genome amplification on endoplasmic reticulum membranes. It has the ability to bind to HCV RNA. It show to have two distinct functions in HCV RNA replication base on phosphorylated states. Maintaining the HCV replication complex mediate by the cis-acting function of basally phosphorylated NS5A and the trans-acting function of hype phosphorylat NS5A modulates HCV assembly and infectious particle formation. Daclatasvir show to disrupt hype phosphorylat NS5A proteins thus interfere with the function of new HCV replication complexes. It also report that daclatasvir also blocks both intracellular viral RNA synthesis and virion assembly/secretion in vivo.
Absorption
Studies demonstrated that peak plasma concentrations typically occurred within 2 hours after administration of multiple oral doses ranging from 1 – 100 mg once daily. Steady state reach after approximately 4 days of once-daily daclatasvir administration. The absolute bioavailability of the tablet formulation is 67%.
Volume of distribution
The approximate volume of distribution of daclatasvir is 47 L in patients who was orally administered 60 mg tablet followed by 100 µg [13C,15N]-daclatasvir intravenously.
Metabolism
Daclastavir is a substrate of CYP3A enzymes where its metabolism predominantly mediate by CYP3A4 isoform. Oxidative pathways included δ-oxidation of the pyrrolidine moiety, resulting in ring opening to an amino aldehyde intermediate follow by an intramolecular reaction between the aldehyde and the proximal imidazole nitrogen atom. High proportion of the drug in the plasma (greater than 97%) in the unchange form.
Contraindications
Strong inducers of CYP3A, including phenytoin, carbamazepine, rifampicin, and
St. John’s wort
Hypersensitivity to the active substance or to any of the excipients
Use in Pregnancy & Lactation
There no data from the use of daclatasvir in pregnant women. Daclatasvir should not use during pregnancy or in women of childbearing potential not using contraception. Use of highly effective contraception continue for 5 weeks after completion of Daclatasvir therapy. It not know whether daclatasvir excrete in human milk.
Drug Interaction
Strong or moderate CYP3A4 or P-gp inducers (eg, phenytoin, carbamazepine, phenobarbital, rifampicin, systemic dexamethasone, St John’s wort) or
Strong CYP3A4 inhibitors (eg, boceprevir, telaprevir, HIV protease inhibitors, cobicistat, macrolides, azole antifungals, calcium channel blockers). NNRTIs, dabigatran, digoxin, oral contraceptives, statins, amiodarone
Commercial Packaging
Virodacla 12:Each box contains 3 blister strips of 4 tablets.
Virodacla 28: Each container contains 28 tablets.
Others
Pediatric Use: The safety and efficacy of Daclatasvir in children and adolescents aged <18 years have not yet been established.
Buy Daclatasvir 60 mg online
Buy Daclatasvir 60 mg online is always costly. But our Virodacla tablet 28’s is an excellent quality medicine with low cost. If you are interested to buy our product than contact us.